Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of LIS1 in Kidney Transplant Recipients
NCT04431219Phase 2Completed
- Sponsor
- Xenothera
- Start
- Nov 2019
- Primary completion
- Mar 2022
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LIS1 in kidney transplant rejection, sponsored by Xenothera. Started Nov 2019; status: completed.
02
Drugs
LIS1
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04431219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04431219.